|
|
|
|
|
|
|
HDL and endotoxemia
|
|
|
|
HDL and atherosclerosis
|
|
|
|
|
SATURN
|
|
|
|
CETP as a therapeutic target
|
|
|
|
CETP in HDL physiology
|
|
|
|
CETP in HDL physiology
|
|
|
|
CETP Genetics and CHD risk
|
|
|
|
CETP genetics and CHD risk
|
|
|
|
Epidemiology of CETP
|
|
|
|
CETP mass and CHD incidence in PROVE-IT
|
|
|
|
The Inhibition of Cholesteryl Ester Transfer Protein
|
|
|
|
Pharmacodynamics of CETP regulation
|
|
|
|
Clinical trials of HDL increase by CETP inhibition
|
|
|
|
Efficacy of anacetrapib in DEFINE
|
|
|
|
Safety of anacetrapib in DEFINE
|
|
|
|
Effects of CETP regulation on plasma lipids
|
|
|
|
Differential regulation of CETP
|
|
|
|
dal-OUTCOMES Study design
|
|
|
|
Testing the HDL paradigm
|
|
|
|
Summary
|
|
Share this page with your colleagues and friends: